Profile data is unavailable for this security.
About the company
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based company primarily engaged in the new drug research and development, preparation production, drug sales, and active pharmaceutical ingredients (API) production. The Company operates two segments. The Infusion segment is mainly engaged in the production and sale of infusion products and the provision of services. The Non-Infusion segment is mainly engaged in the production and sale of non-infusion products and the provision of services. The Company's chronic disease business products include compound reserpine triamterene tablets, gliquidone tablets and others. The Company's specialty business products include teniposide injection, busulfan injection and others. The Company's infusion business products include basic infusion, therapeutic infusion, nutritional infusion and other multi-category infusion products. The Company's API business products include valsartan, amlodipine, pregabalin and others.
- Revenue in CNY (TTM)10.95bn
- Net income in CNY1.58bn
- Incorporated1997
- Employees13.41k
- LocationChina Resources Double-Crane Pharmaceutical Co LtdNo.1 Lize East Er RoadWangjing, Chaoyang DistrictBEIJING 100102ChinaCHN
- Phone+86 1 064398099
- Fax+86 1 064398086
- Websitehttps://www.dcpc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jinyu Bio-Technology Co Ltd | 1.33bn | 100.76m | 17.22bn | 1.74k | 218.17 | 3.15 | -- | 12.98 | 0.071 | 0.071 | 1.27 | 4.92 | 0.1946 | 2.45 | 1.89 | 762,676.30 | 1.37 | 4.31 | 1.56 | 5.06 | 50.46 | 57.76 | 7.02 | 17.99 | 3.09 | -- | 0.0029 | 36.89 | -21.45 | 2.19 | -61.57 | -13.19 | -21.84 | -12.94 |
| Tonghua Dongbao Pharmaceutical Co Ltd | 2.74bn | 1.23bn | 17.41bn | 3.41k | 14.18 | 2.44 | -- | 6.35 | 0.6271 | 0.6271 | 1.40 | 3.64 | 0.3589 | 1.05 | 5.11 | 803,924.60 | 15.84 | 14.89 | 17.08 | 15.68 | 71.05 | 78.86 | 44.15 | 35.26 | 3.49 | -- | 0.0988 | 50.60 | -34.66 | -6.27 | -103.66 | -- | 14.17 | 4.56 |
| Shandong Buchang Pharmaceuticals Co Ltd | 10.96bn | 1.66m | 18.32bn | 7.69k | 2,546.92 | 1.73 | -- | 1.67 | 0.0068 | 0.0068 | 10.34 | 10.03 | 0.5519 | 0.9196 | 13.73 | 1,425,409.00 | -0.6503 | 0.8521 | -0.9366 | 1.25 | 62.31 | 70.57 | -1.18 | 1.32 | 0.4929 | 3.23 | 0.2758 | 157.32 | -16.91 | -5.04 | -273.62 | -- | -21.53 | -- |
| Liaoning Cheng Da Co Ltd | 11.12bn | 862.79m | 18.68bn | 3.32k | 21.24 | 0.6349 | -- | 1.68 | 0.575 | 0.575 | 7.27 | 19.23 | 0.2277 | 5.72 | 5.88 | 3,352,748.00 | 2.94 | 3.15 | 4.13 | 4.55 | 12.07 | 13.95 | 12.89 | 9.88 | 0.9357 | -- | 0.2586 | 16.44 | 4.70 | -8.65 | -10.09 | -29.33 | -9.31 | -27.52 |
| China Resources Dubl-Crne Phrmctl Co Ltd | 10.95bn | 1.58bn | 19.42bn | 13.41k | 12.20 | 1.72 | -- | 1.77 | 1.53 | 1.53 | 10.62 | 10.90 | 0.6524 | 2.99 | 5.05 | 816,058.20 | 9.70 | 8.90 | 13.45 | 11.99 | 56.61 | 57.39 | 14.86 | 13.13 | 1.75 | -- | 0.0904 | 33.53 | -0.8711 | 3.63 | -2.19 | 9.06 | 21.41 | 9.15 |
| BrightGene Bio-Medical Technology Co Ltd | 1.18bn | 62.08m | 19.57bn | 1.15k | 310.62 | 8.00 | -- | 16.59 | 0.1489 | 0.1489 | 2.82 | 5.79 | 0.2305 | 1.61 | 3.38 | 1,025,174.00 | 0.5058 | 5.25 | 0.6383 | 6.47 | 51.53 | 56.22 | 2.19 | 17.55 | 0.9402 | 1.23 | 0.4935 | 21.32 | 8.74 | 20.58 | -6.57 | 11.23 | 23.50 | 3.20 |
| Joincare Pharmaceutical Group Ind. Co. | 15.20bn | 1.37bn | 21.40bn | 14.35k | 15.78 | 1.44 | -- | 1.41 | 0.7413 | 0.7413 | 8.24 | 8.13 | 0.4211 | 2.40 | 5.51 | 1,059,126.00 | 8.29 | 8.60 | 17.45 | 18.66 | 61.28 | 62.42 | 19.70 | 17.66 | 2.38 | -- | 0.1776 | 27.59 | -6.17 | 5.45 | -3.90 | 9.17 | 6.84 | 4.56 |
| Holder | Shares | % Held |
|---|---|---|
| Harvest Fund Management Co., Ltd.as of 31 Mar 2025 | 10.78m | 1.05% |
| Monetary Authority of Macao (Investment Management)as of 31 Mar 2025 | 6.12m | 0.60% |
| China Southern Asset Management Co., Ltd.as of 31 Mar 2025 | 5.47m | 0.53% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 4.66m | 0.45% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 4.02m | 0.39% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 2.64m | 0.26% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 1.36m | 0.13% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.34m | 0.13% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 1.27m | 0.12% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 1.27m | 0.12% |
